Pathophysiology of Migraine — New Insights

Canadian Journal of Neurological Sciences

Volumn 26, Issue 3, 1999, Pages 12-19

  Hargreaves, Rj ^a   Shepheard, Sl ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; ALMOTRIPTAN; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE ANTAGONIST; DIAZEPAM; ELETRIPTAN; ERGOT DERIVATIVE; FROVATRIPTAN; LANEPITANT; NARATRIPTAN; NEUROKININ 1 RECEPTOR ANTAGONIST; PNU 142633; RECEPTOR SUBTYPE; RIZATRIPTAN; RP 100893; SEROTONIN 1 AGONIST; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANTINOCICEPTION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; HEADACHE; HUMAN; MIGRAINE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; VASOCONSTRICTION;

BRAIN; CALCITONIN GENE-RELATED PEPTIDE; HUMANS; MIGRAINE DISORDERS; NEURAL PATHWAYS; NOCICEPTORS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; TRIGEMINAL NERVE;

EID: 0032718724     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100000147     Document Type: Article

References (67)

1. Ophoff, RA, Terwindt, GM, Vergouwe, MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996; 87: 543–552.
2. Frants, RR, Ophoff, RA, Terwindt, GM. The future of headache genetics. In: Olesen, J, Bouser, M-G, eds. Genetics of Headache Disorders. New York: Lippincott-Raven, 1998.
3. Hans, M, Luvisetto, S, Williams, ME, et al. Functional consequences of mutations in the human α 1A calcium channel subunit linked to familial hemiplegic migraine. J Neurosci. 1999; 19: 1610–1619.
4. Ferrari, M. Migraine. Lancet. 1998; 351: 1043–1051.
5. Lauritzen, M. Pathophysiology of the migraine aura: the spreading depression theory. Brain. 1994; 117: 199–210.
6. Welch, KMA. Pathogenesis of migraine. Sem Neurol. 1997; 17: 335–341.
7. Cutrer, FM, Sorensen, G, Weisskof, R, et al. Perfusion weighted imaging defects during spontaneous migraine aura. Ann Neurol. 1998; 43: 25–31.
8. Read, SJ, Parsons, AA. Cortical spreading depression in migraine. In: Edvinsson, L, ed. Migraine and Headache Pathophysiology. London: Martin Dunitz, 1999: 81–92.
9. Raskin, NH, Hosobuchi, Y, Lamb, S. Headache may arise from perturbation of the brain. Headache. 1987; 27: 416–420.
10. Weiller, C, May, A, Limmroth, V, et al. Brain stem activation in spontaneous human migraine attacks. Nature Med. 1995; 1: 658–660.
11. May, A, Bahra, A, Buchel, C, Frackowy, PJ. Hypothalamic activation in cluster headache attacks. Lancet. 1998; 352: 275–278.
12. May, A, Kaube, H, Buchel, C, et al. Experimental cranial pain elicited by capsaicin: a PET study. Pain. 1998; 74: 61–66.
13. Welch, KMA, 1 Cao, Y, Aurora, S, et al. MRI of the occipital cortex, rednucleus and substantia nigra during visual aura of migraine. Neurology. 1998; 51: 1465–1469.
14. Cerbo, R, Barbanti, P, Buzzi, MG, et al. Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin Neuropharmacol. 1997; 20: 36–41.
15. Peroutka, SJ. Dopamine and migraine. Neurology. 1997; 49: 1231–1238.
16. Dahlof, CGH, Hargreaves, RJ. Pathophysiology and pharmacology of migraine. Is there a place for anti-emetics in future treatment strategies? Cephalalgia. 1998; 18: 593–604.
17. Aurora, SK, Ahmad, BK, Welch, KM, Bhardhwaj, P, Ramadan, NM. Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology. 1998; 50: 1111–1114.
18. Afra, J, Mascia, A, Gerard, P, Maertens de Noordhout, A, Schoenen, J. Interictal cortical excitability in migraine: a study using transcranial magnetic stimulation of motor and visual cortices. Ann Neurol. 1998; 44: 209–215.
19. Ray, BS, Wolff, HG. Experimental studies on headache: pain sensitive structures of the head and their significance in headache. Arch Surgery. 1940; 41: 813–856.
20. Wolff, HG. Headache and Other Head Pain. New York: Oxford University Press, 1963.
21. Moskowitz, MA. The neurobiology of vascular head pain. Ann Neurol. 1984; 16: 157–168.
22. Moskowitz, MA. The visceral organ brain: implications for the pathophysiology of vascular head pain. Neurology. 1991; 41: 182–186.
23. Gebhart, GF. Visceral pain mechanisms: relevance to migraine. In: Olesen, J, Moskowitz, MA, eds. Experimental Headache Models. Philadelphia: Lippincott-Raven Publishers, 1995: 39q–47.
24. Fozard, JR. 5-hydroxytryptamine and nitric oxide: the causal relationship between two endogenous precipitants of migraine. In: Sandler, M, Ferrari, M and Harnett, S, eds. Migraine Pharmacology and Genetics. Chapman and Hall: London, 1996: 167–179.
25. Olesen, J, Thomsen, LL, Iversen, H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci. 1994; 15: 149–153.
26. Thomsen, LL, Olesen, J. Experimental vascular headache models in man. In: Edvinsson, L, ed. Migraine and Headache Pathophysiology. London: Martin Dunitz, 1999: 141–154.
27. Lassen, LH, Ashina, M, Christiansen, I, Ulrich, V, Olesen, J. Nitric oxide synthase inhibition in migraine. Lancet. 1997; 349: 401.
28. Humphrey, PP, Feniuk, W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci. 1991; 12: 444–446.
29. Goadsby, PJ, Edvinsson, L, Ekman, R. Vasoactive neuropeptide release in the extracerebral circulation during migraine headache. Ann Neurol. 1990; 28: 183–187.
30. Goadsby, PJ, Edvinsson, L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuro-peptide changes seen in humans and cats. Ann Neurol. 1993; 33: 48–56.
31. Goadsby, PJ, Zagami, AS, Lambert, GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache. 1991; 31: 365–371.
32. Strassman, AM, Raymond, SA, Burstein, R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996; 384: 560–564.
33. Burstein, R, Yamamura, H, Malick, A, Strassman, AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998; 79: 964–982.
34. Cumberbatch, MJ, Williamson, DJ, Mason, GS, Hill, RG, Hargreaves, RJ. Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol. 1999; 126: 1478–1486.
35. Hamel, E, Fan, E, Linville, D, et al. Expression of mRNA for the serotonin 5-hydroxytryptamine1Dß receptor subtype in human and bovine cerebral arteries. Mol Pharmacol. 1993; 44: 242–246.
36. Longmore, J, Shaw, D, Smith, D, et al. Differential distribution of 5-HT1D- and 5-HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new anti-migraine drugs. Cephalalgia. 1997; 17: 835–842.
37. Longmore, J, Razzaque, Z, Shaw, D, et al. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistochemical demonstration of the involvement of 5-HT1B receptors. Br J Clin Pharmacol. 1998; 46: 577–582.
38. Bouchelet, I, Cohen, Z, Case, B, Seguela, P, Hamel, E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol. 1998; 50: 219–223.
39. Rebeck, GW, Maynard, KI, Hyman, BT, Moskowitz, MA. Selective 5-HT1D serotonin gene receptor expression in trigeminal ganglia. Proc Natl Acad Sci USA. 1994; 91: 3666–3669.
40. Bruinvels, AT, Landwehrmeyer, B, Gustafson, EL, et al. Localization of 5-HT1B, 5-HT1Da, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 1994; 33: 367–386.
41. Pascual, J, Castro, ME, Romon, T, et al. Anatomical distribution of 5-HT1F receptors in the human brain suggests a role in migraine. Cephalalgia. 1997; 17: 341.
42. Castro, ME, Pascual, J, Romon, T, et al. Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brain stem and spinal cord. Neuropharmacology. 1997; 36: 535–542.
43. Cohen, ML, Johnson, KW, Schenck, KW. Lack of vasoconstriction to the selective 5-HT1F receptor agonists LY334370 and LY344864 in the rabbit saphenous vein (RSV), a model for coronary and cerebral vasoconstrictor activity. Proceedings of the 4th IUPHAR satellite meeting on Serotonin, 23-25th July, Rotterdam, 1998: 38.
44. Hoyer, D, Clarke, DE, Fozard, JR, et al. The IUPHAR classification of receptors for 5-hydroxytriptamine (serotonin). Pharmacol Rev. 1994; 46: 157–204.
45. Silberstein, SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997; 37(suppl. 1) S15–S25.
46. Martin, GR, Rohdes, P, Mills, A. Autoradiographic mapping of receptors and recognition sites for established and putative antimigraine drugs. In: Edvinsson, L, ed, Migraine and Headache Pathophysiology. London: Martin Dunitz, 1999: 63–80.
47. Pauwels, PJ, Tardif, S, Palmier, C, Wurch, T, Colpaert, FC. How efficacious are 5-HT1B/1D receptor ligands: an answer from GTPgS binding studies with stably transfected C6-glial cell lines. Neuropharmacology. 1997; 36: 499–512.
48. Longmore, J, Dowson, AJ, Hill, RG. Current Opinion in CPNS Investigational Drugs. 1999; 1: 39–53.
49. Shepheard, SL, Williamson, DJ, Beer, MS, Hill, RG, Hargreaves, RJ. Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology. 1997; 36: 525–533.
50. Williamson, DJ, Hargreaves, RJ, Hill, RG, Shepheard, SL. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia. 1997; 17: 518–524.
51. Kaube, H, Hoskin, KL, Goadsby, PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol. 1993; 109: 788–792.
52. Cumberbatch, MJ, Hill, RG, Hargreaves, RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 1997; 328: 37–40.
53. Cumberbatch, MJ, Hill, RG, Hargreaves, RJ. Differential effects of naratriptan on spinal versus trigeminal nociceptive responses. Cephalalgia. 1997; 17: 381.
54. Tfelt-Hansen, P, Teall, J, Rodriguez, F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache. 1998; 38: 748–755.
55. Cumberbatch, MJ, Hill, RG, Hargreaves, RJ. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anesthetized rats. Eur J Pharmacol. 1998; 362: 43–46.
56. Connor, HE, Fenuik, W, Humphrey, PPA. 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol. 1989; 161: 91–94.
57. MaassenVanDenBrink, A, Reekers, M, Bax, WA, Ferrari, MD, Saxena, PR. Coronary side-effect potential of current and prospective anti-migraine drugs. Circulation. 1998; 98: 25–30.
58. Longmore, J, Hargreaves, RJ, Boulanger, CM, et al. Comparison of the vasoconstrictor properties of the 5-HT1D receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Functional Neurology. 1997; 12: 1–9.
59. Hargreaves, RJ, Williamson, DJ, Shepheard, SL. Neurogenic inflammation: relation to novel antimigraine drugs. In: Edvinsson, L, ed. Migraine and Headache Pathophysiology. London: Martin Dunitz, 1999: 93–102.
60. Shepheard, SL, Williamson, DJ, Hill, RG, Hargreaves, RJ. The nonpeptide neurokinin1 receptor antagonists RP67580 blocks neurogenic plasma extravasation in the dura mater of rats. Br J Pharmacol. 1993; 108: 11–12.
61. Williamson, DJ, Shepheard, SL, Hill, RG, Hargreaves, RJ. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vaso-dilation and extravasation. Eur J Pharmacol. 1997; 328: 61–64.
62. Maura, G, Marcoli, M, Tortarolo, M, Andrioli, GC, Raiteri, M. Glutamate release in human cerebral cortex and its modulation by 5-hydroxytriptamine acting at h5-HT1D receptors. Br J Pharmacol. 1998; 123: 45–50.
63. Pregenzer, JF, Alberts, GL, Im, WB, et al. Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands). Br J Pharmacol. 1999; 127: 468–472.
64. Johnson, KW, Schaus, JM, Durkin, MM, et al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. NeuroReport. 1997; 8: 2237–2240
65. Schaus, JM, Audia, JE, Dressman, BA. LY334370 is a high affinity, selective 5-HT1F receptor agonist. Cephalalgia. 1997; 17: 398.
66. Goldstein, DJ, Roon, KJ, Offen, WW, et al. Migraine treatment with selective 5-HT1F receptor agonist (SSOFRA) LY334370. Cephalagia. 1999; 19: 318 (abstract Proceedings of the 9th Congress of the IHS, Barcelona, Spain, June 1999).
67. Pereira, A, Granier, LA, Vandenhende, F, de Suray, JM, Onkelinx, C. Safety and pharmacokinetics of high doses of LY 334870, a selective serotonin 1F receptor agonist (SSOFRA) during and outside an acute migraine attack. Cephalagia. 1999; 19: 368 (abstract Proceedings of the 9th Congress of the IHS, Barcelona, Spain, June 1999).